Jollimex 150 Capsule contains Mexiletine 150 mg, a class 1B antiarrhythmic agent used primarily for the management of ventricular arrhythmias. Mexiletine acts by blocking sodium channels in cardiac cells, thereby stabilizing the cardiac membrane and reducing abnormal electrical activity that can lead to arrhythmias. It is indicated for the treatment of life-threatening ventricular arrhythmias such as ventricular tachycardia and ventricular fibrillation, particularly in patients who are unresponsive or intolerant to other antiarrhythmic therapies. Jollimex 150 is administered orally and is well absorbed from the gastrointestinal tract, with a bioavailability that allows for effective plasma concentrations to be maintained with regular dosing. The medication should be used under strict medical supervision due to potential side effects, which may include gastrointestinal disturbances, dizziness, tremors, and in rare cases, proarrhythmic effects. Caution is advised in patients with hepatic impairment, severe cardiac conduction abnormalities, or a history of hypersensitivity to Mexiletine. Regular monitoring of cardiac function and plasma drug levels is recommended to optimize therapeutic efficacy and minimize adverse reactions. Jollimex 150 Capsule provides an essential option in the pharmacological management of serious ventricular arrhythmias, contributing to improved cardiac rhythm control and patient outcomes.